vs

Side-by-side financial comparison of Ascendis Pharma A/S (ASND) and HECLA MINING CO (HL). Click either name above to swap in a different company.

HECLA MINING CO is the larger business by last-quarter revenue ($448.1M vs $267.3M, roughly 1.7× Ascendis Pharma A/S). On growth, HECLA MINING CO posted the faster year-over-year revenue change (79.5% vs 42.3%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 53.8%).

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

Hecla Mining is a leading U.S.-based precious and base metals mining firm. Core products include silver, gold, lead and zinc, with operating assets across North America. It supplies raw materials to global jewelry manufacturing, industrial production, and renewable energy segments, and is a top domestic primary silver producer.

ASND vs HL — Head-to-Head

Bigger by revenue
HL
HL
1.7× larger
HL
$448.1M
$267.3M
ASND
Growing faster (revenue YoY)
HL
HL
+37.2% gap
HL
79.5%
42.3%
ASND
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
53.8%
HL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASND
ASND
HL
HL
Revenue
$267.3M
$448.1M
Net Profit
$134.4M
Gross Margin
90.5%
55.4%
Operating Margin
49.1%
Net Margin
30.0%
Revenue YoY
42.3%
79.5%
Net Profit YoY
1027.2%
EPS (diluted)
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASND
ASND
HL
HL
Q4 25
$267.3M
$448.1M
Q3 25
$230.7M
$409.5M
Q2 25
$170.7M
$304.0M
Q1 25
$109.0M
$261.3M
Q4 24
$187.8M
$249.7M
Q3 24
$62.5M
$245.1M
Q2 24
$38.9M
$245.7M
Q1 24
$103.6M
$189.5M
Net Profit
ASND
ASND
HL
HL
Q4 25
$134.4M
Q3 25
$-65.9M
$100.7M
Q2 25
$-42.0M
$57.7M
Q1 25
$-102.2M
$28.9M
Q4 24
$11.9M
Q3 24
$-107.1M
$1.8M
Q2 24
$-118.1M
$27.9M
Q1 24
$-141.5M
$-5.8M
Gross Margin
ASND
ASND
HL
HL
Q4 25
90.5%
55.4%
Q3 25
89.5%
44.1%
Q2 25
80.1%
39.3%
Q1 25
82.6%
28.3%
Q4 24
91.9%
27.4%
Q3 24
80.6%
24.2%
Q2 24
68.2%
20.9%
Q1 24
92.1%
10.1%
Operating Margin
ASND
ASND
HL
HL
Q4 25
49.1%
Q3 25
5.1%
36.3%
Q2 25
-33.5%
30.8%
Q1 25
-103.2%
20.0%
Q4 24
15.3%
Q3 24
-167.3%
9.2%
Q2 24
-370.2%
16.5%
Q1 24
-51.2%
2.7%
Net Margin
ASND
ASND
HL
HL
Q4 25
30.0%
Q3 25
-28.5%
24.6%
Q2 25
-24.6%
19.0%
Q1 25
-93.7%
11.0%
Q4 24
4.8%
Q3 24
-171.5%
0.7%
Q2 24
-303.9%
11.3%
Q1 24
-136.6%
-3.0%
EPS (diluted)
ASND
ASND
HL
HL
Q4 25
$0.20
Q3 25
$0.15
Q2 25
$0.09
Q1 25
$0.05
Q4 24
$0.03
Q3 24
$0.00
Q2 24
$0.04
Q1 24
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASND
ASND
HL
HL
Cash + ST InvestmentsLiquidity on hand
$665.3M
$301.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$-175.8M
$2.6B
Total Assets
$1.4B
$3.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASND
ASND
HL
HL
Q4 25
$665.3M
$301.2M
Q3 25
$582.2M
$133.9M
Q2 25
$533.6M
$296.6M
Q1 25
$559.4M
$23.7M
Q4 24
$604.3M
$26.9M
Q3 24
$675.6M
$22.3M
Q2 24
$279.4M
$24.6M
Q1 24
$345.9M
$80.2M
Stockholders' Equity
ASND
ASND
HL
HL
Q4 25
$-175.8M
$2.6B
Q3 25
$-188.0M
$2.4B
Q2 25
$-202.6M
$2.3B
Q1 25
$-205.0M
$2.1B
Q4 24
$-114.2M
$2.0B
Q3 24
$-105.1M
$2.0B
Q2 24
$-346.8M
$2.0B
Q1 24
$-257.2M
$2.0B
Total Assets
ASND
ASND
HL
HL
Q4 25
$1.4B
$3.6B
Q3 25
$1.2B
$3.2B
Q2 25
$1.2B
$3.3B
Q1 25
$1.1B
$3.0B
Q4 24
$1.3B
$3.0B
Q3 24
$1.2B
$3.0B
Q2 24
$819.0M
$2.9B
Q1 24
$866.7M
$3.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASND
ASND
HL
HL
Operating Cash FlowLast quarter
$58.2M
$217.1M
Free Cash FlowOCF − Capex
$134.7M
FCF MarginFCF / Revenue
30.1%
Capex IntensityCapex / Revenue
18.4%
Cash ConversionOCF / Net Profit
1.61×
TTM Free Cash FlowTrailing 4 quarters
$310.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASND
ASND
HL
HL
Q4 25
$58.2M
$217.1M
Q3 25
$148.0M
Q2 25
$161.8M
Q1 25
$-15.5M
$35.7M
Q4 24
$-330.7M
$67.5M
Q3 24
$55.0M
Q2 24
$78.7M
Q1 24
$-109.7M
$17.1M
Free Cash Flow
ASND
ASND
HL
HL
Q4 25
$134.7M
Q3 25
$90.1M
Q2 25
$103.8M
Q1 25
$-18.4M
Q4 24
$6.7M
Q3 24
$-690.0K
Q2 24
$28.3M
Q1 24
$-30.5M
FCF Margin
ASND
ASND
HL
HL
Q4 25
30.1%
Q3 25
22.0%
Q2 25
34.1%
Q1 25
-7.0%
Q4 24
2.7%
Q3 24
-0.3%
Q2 24
11.5%
Q1 24
-16.1%
Capex Intensity
ASND
ASND
HL
HL
Q4 25
18.4%
Q3 25
14.1%
Q2 25
19.1%
Q1 25
20.7%
Q4 24
24.3%
Q3 24
22.7%
Q2 24
20.5%
Q1 24
25.1%
Cash Conversion
ASND
ASND
HL
HL
Q4 25
1.61×
Q3 25
1.47×
Q2 25
2.80×
Q1 25
1.24×
Q4 24
5.66×
Q3 24
31.24×
Q2 24
2.82×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASND
ASND

Segment breakdown not available.

HL
HL

Silver Contracts$258.5M58%
Gold$129.2M29%
Zinc$30.3M7%
Lead$23.3M5%
Environmental Remediation Services$9.2M2%

Related Comparisons